Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shannon R Morris

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Oncology (Williston Park, N.Y.)|February 1, 2007
Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancerShannon R Morris, Lisa A Carey
Current Opinion in Oncology|October 2, 2007
Gene expression profiling in breast cancerShannon R Morris, Lisa A Carey
Reviews in Endocrine & Metabolic Disorders|April 28, 2007
Molecular profiling in breast cancerShannon R Morris, Lisa A Carey
World Journal of Gastroenterology|July 1, 2006
Acute liver failure due to natural killer-like T-cell leukemia/lymphoma: a case report and review of the literatureEvan S Dellon, Shannon R Morris, Wozhan Tang, et al.
Clinical Lung Cancer|April 25, 2021
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled StudiesJared Weiss, Jerome Goldschmidt, Zoran Andric, et al.
Journal of Clinical Pharmacology|March 12, 2010
Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarinLyndon C Kirby, Brendan M Johnson, Laurel M Adams, et al.
Blood|July 31, 2014
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myelomaAndrew Spencer, Sung-Soo Yoon, Simon J Harrison, et al.
International Journal of Cancer|December 21, 2020
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trialDavey Daniel, Vladimer Kuchava, Igor Bondarenko, et al.
Oncotarget|October 27, 2015
A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathwayAzadeh Cheraghchi-Bashi, Christine A Parker, Ed Curry, et al.
Cancer Medicine|August 18, 2021
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trialsRenata Ferrarotto, Ian Anderson, Balazs Medgyasszay, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Oncology (Williston Park, N.Y.)|February 1, 2007
Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancerShannon R Morris, Lisa A Carey
Current Opinion in Oncology|October 2, 2007
Gene expression profiling in breast cancerShannon R Morris, Lisa A Carey
Reviews in Endocrine & Metabolic Disorders|April 28, 2007
Molecular profiling in breast cancerShannon R Morris, Lisa A Carey
World Journal of Gastroenterology|July 1, 2006
Acute liver failure due to natural killer-like T-cell leukemia/lymphoma: a case report and review of the literatureEvan S Dellon, Shannon R Morris, Wozhan Tang, et al.
Clinical Lung Cancer|April 25, 2021
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled StudiesJared Weiss, Jerome Goldschmidt, Zoran Andric, et al.
Journal of Clinical Pharmacology|March 12, 2010
Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarinLyndon C Kirby, Brendan M Johnson, Laurel M Adams, et al.
Blood|July 31, 2014
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myelomaAndrew Spencer, Sung-Soo Yoon, Simon J Harrison, et al.
International Journal of Cancer|December 21, 2020
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trialDavey Daniel, Vladimer Kuchava, Igor Bondarenko, et al.
Oncotarget|October 27, 2015
A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathwayAzadeh Cheraghchi-Bashi, Christine A Parker, Ed Curry, et al.
Cancer Medicine|August 18, 2021
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trialsRenata Ferrarotto, Ian Anderson, Balazs Medgyasszay, et al.
Pageof 2